Clinical Laboratory Scientist (CLS), Prenatal (contractor) at BillionToOne

Union City, California, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Part TimeJob Type

UnknownVisa

Healthcare, Biotechnology, DiagnosticsIndustries

Requirements

Bachelor's degree in the chemical, physical or biological sciences
0-2 years of CLS experience in a clinical setting
A current California Clinical Laboratory Scientist License that meets requirements for Testing Personnel under CLIA regulations (42 CFR, part 493) (California, CGMBS or Generalist license is required)
Advanced knowledge of Google Docs, Word, Excel, basic statistics and familiarity with LIMS systems
Strong attention to detail and ability to work flexibly and well under given timeframes
Self-starter and dynamic team player with excellent verbal and written skills

Responsibilities

Performs clinical laboratory assays to provide data for diagnosis, treatment, and prevention of disease
Performs quality control studies to ensure the accuracy of clinical data
Verifies instrument performance by checking and calibrating specific lab instruments and documents data
Contributes to troubleshooting, training, and continuous process improvement

Skills

California CLS License

CLIA

NIPT

Molecular Diagnostics

Blood Sample Processing

Laboratory Assays

Prenatal Testing

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters

2016Year Founded

$380.2MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.

Rapid technological advancements may render their current technology obsolete.

Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.

Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.

They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.

Their new Austin facility will create 1,000 jobs, boosting production and local economy.

Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI

Try Jobo Free